Chinese Biotech Peptide Pipeline Expanded Across the Week With Gan & Lee Pharmaceuticals Initiating a Phase II Clinical Trial of GZR102 (a Basal Insulin/GLP-1RA Fixed-Dose Weekly Formulation) on August 8, 2026 and Registering a Phase I Study of GZR18 on August 15; Xianweida Registered XW003 (Ecnoglutide) Phase I Clinical Trial for Adolescent Obesity on August 8; Wayne Biotech WBD156 Capsule Advanced Through Development; Fujian Genorup Semaglutide Pipeline Expanded; The Week's Pattern Extends the Chinese Biotech GLP-1 Ambition That Now Spans Ribupatide (Hengrui-Kailera, Global Phase 3 H1 2027), Mazdutide (Innovent, GLP-1/Glucagon Dual Agonist in Late-Stage Trials), MWN105 (Minwei Bio, Semaglutide-Intolerant Population), and IBI3032 (Innovent, FDA IND August 5)
Chinese biotech peptide pipeline expanded across the week ending August 22, 2026. Key registrations and advances: Gan & Lee Pharmaceuticals initiated a Phase II clinical trial of GZR102 (a basal insulin plus GLP-1 receptor agonist fixed-dose weekly formulation) on August 8, targeting patients requiring both basal glycemic control and appetite-and-glucose modulation from a single weekly injection; Gan & Lee also registered a Phase I study of GZR18 on August 15. Xianweida registered XW003 (ecnoglutide) Phase I clinical trial for adolescent obesity on August 8, extending the ecnoglutide franchise into pediatric obesity development after the adult Phase 3 EECOH-2 win. Wayne Biotech WBD156 capsule (oral peptide candidate) advanced through preclinical/early-clinical development. Fujian Genorup's semaglutide pipeline expanded across multiple formulation and indication programs. The week's pattern extends the broader Chinese biotech GLP-1 pipeline expansion that now spans ribupatide (Hengrui-Kailera, once-weekly injectable GLP-1/GIP/glucagon triple agonist, global Phase 3 planned H1 2027), mazdutide (Innovent, GLP-1/glucagon dual agonist in late-stage Chinese and US trials), MWN105 (Minwei Bio, targeting semaglutide-intolerant populations), IBI3032 (Innovent, FDA IND clearance August 5), and multiple additional candidates. The synchronized China+US development pattern reflects the increasing sophistication of Chinese biotech clinical strategy targeting global markets rather than China-only launches.